Cardiovascular Devices Market - Global Forecast To 2029
商品番号 : SMB-71992
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年1月 |
| ページ数 | 429 |
| 図表数 | 516 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global cardiovascular devices market is USD 77.71 billion in 2024 and is projected to reach USD 110.39 billion by 2029, at a CAGR of 7.3 % during the forecast period.
世界の心臓血管用デバイス市場は2024年に777億1,000万米ドルで、予測期間中のCAGRは7.3%で、2029年までに1,103億9,000万米ドルに達すると予測されています。
The growth of the cardiovascular devices market is driven by several key factors, most notably the increasing prevalence of cardiovascular diseases (CVD) worldwide, advancements in minimally invasive procedures, and growing demand for improved patient outcomes and lastly shifting preference to remote monitoring. As rates of heart disease rise, the need for effective monitoring and treatments such as angioplasty, stenting, and valve replacements also increases where these devices are implemented. Technological innovations, including the development of drug-eluting stents, bioresorbable scaffolds and occluders, and advanced imaging technologies, have enabled safer and more precise procedures, which contribute to the market’s growth.
心臓血管用デバイス市場の成長は、いくつかの重要な要因によって推進されており、最も顕著なのは、世界的な心血管疾患（CVD）の有病率の増加、低侵襲処置の進歩、患者転帰の改善に対する需要の高まり、そして最後に遠隔モニタリングへの優先の移行です。心臓病の発生率が上昇するにつれて、血管形成術、ステント留置術、弁置換術などの効果的なモニタリングと治療の必要性も、これらの装置が導入されている地域では増加しています。薬剤溶出性ステント、生体吸収性足場と閉塞材、高度な画像技術の開発などの技術革新により、より安全で正確な処置が可能になり、市場の成長に貢献しています。
“Based on the product type, the the cardiac imaging and diagnostic device segment holds a significant share the cardiovascular devices market.”
Cardiac imaging and diagnostic devices include a range of medical technologies used to visualize the heart and assess its functions, enabling the detection, diagnosis, and monitoring of heart diseases. These devices provide detailed images of the heart’s structure, blood flow, and electrical activity. The cardiac imaging and diagnostic devices segment is the one to grow at the highest rate in the cardiovascular devices market. This is due to growing global burden of cardiovascular diseases, advancing imaging technologies, rising importance of early diagnosis, and precision medicine. As it is CVDs remain the leading cause of mortality throughout the world, demands increasingly accurate and non-invasive diagnostic tools. Advancements like real-time 3D echocardiography, cardiac MRI, and AI-assisted imaging solutions also significantly enhance the diagnostic efficiency concerning the quality of care for patients and lead to the adoption of such devices among healthcare providers. Apart from this, prevalence of chronic diseases, which increases the risk for heart-related issues, further presses upon continuous cardiac monitoring and the demand for early detection. Government initiatives and healthcare reimbursement policies in the advanced as well as emerging markets drive the adoption of advanced imaging devices. Telehealth capabilities and portable diagnostic devices also make it more accessible, supporting broader market penetration.
“The Coronary artery disease segment holds the largest market share in cardiovascular devices market.”
Coronary heart disease occurs when plaque (atherosclerosis) builds up inside the coronary arteries, that feed blood to the heart muscle, and narrows or blocks them. Thereby, breathlessness or angina may result from heart muscle not receiving enough oxygen rich blood. In extreme cases, heart attack or myocardial infarction may occur due to a total blockage of the coronary artery.Some of the major causes for CAD include an unhealthy lifestyle, including a diet full of saturated fats, lack of exercise, and smoking, which cause damage to the arteries over time. Other factors that contribute to this condition include hypertension, high cholesterol levels, diabetes, and obesity, all of which further the development of plaque. Genetic disposition, age, and chronic stress also add to the development of CAD due to their general impact on the heart and blood vessels. The increasing incidence of the above factors coupled with hightened awareness among the popuation regarding therse diseases would aid in market growth.
“Based on the end user, Others segment is expected to grow by the significant CAGR in the cardiovascular devices market.
The “others” segment, which includes applications like general health checkup, fitness, and wellness monitoring, intraoperative monitoring, and post-op care, is growing the fastest in the cardiovascular device market. This is because of increased focus on preventive care, personalized medicine, and holistic patient care. With the ever-growing awareness on the importance of regular cardiovascular monitoring, there are growing demands for wearable and connected devices which measure parameters including heart rate, blood pressure, and ECG among healthy patients and chronic diseases patients. Advanced intraoperative monitoring equipment during surgery helps assess patients’ hearts real time in safety for patient comfort and best surgical results. Additionally, monitoring devices post-surgery will help track the recovery, early detection of complications, and minimize hospital readmission rates. Integration of AI and IoT into these devices improves the accuracy of data, patient engagement, and clinician decision-making. On the other hand, adoption of telehealth and remote patient monitoring technologies is growing and allows the continuation of care outside the clinical setting.
“Asia Pacific to grow with the highest CAGR in the Cardiovascular devices market during the forecast period.”
The Asia-Pacific region is also expected to experience maximum growth in the cardiovascular devices market in the next few years due to several key factors. Growth is driven by an increasingly aging population, the growing prevalence of cardiovascular diseases, and increased adoption of minimally invasive procedures, especially in countries such as China, Japan, and India. Increased healthcare expenses and development of health infrastructure promote the availability of high-end interventional cardiology services throughout the region.
The break up of the profile of primary participants in the cardiovascular devices market:
- By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%
- By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%.
- By Region: North America – 40%, Europe – 30%, APAC –20%, Latin America – 5%,Middle East & Africa–5%
Key players in the cardiovascular devices market
Some of the prominent players operating in the cardiovascular devices market include Medtronic Plc (Ireland), Abbott Laboratories (US), Boston Scientific Corporation (US), Terumo Corporation (Japan), GE Healthcare Technologies, Inc. (US), Edward Lifesciences Corporation (US), Siemens Healthineers AG (Germany), Johnson & Johnson (US), Baxter International Inc (US), B. Braun SE (Germany), Getinge AB (Sweden), Koninklijke Philips N.V. (Netherlands), Lepu Medical Technology (Beijing) Co., Ltd (China), Nihon Kohden Corporation (Japan), MicroPort Scientific Corporation (China), Japan Lifeline Co., Ltd. (Japan), AngioDynamics, Inc.(US), LifeTech Scientific Corporation (China), Artivion Inc (US), Sahajanand Medical Technologies Limited (India), OrbusNeich Medical Group Holdings Limited (China), BPL Medical Technologies (India), BiotroniK. (Germany),), W.L. Gore & Associates, Inc (US), Canon medical systems corporation (Japan), Picard Medical Company (US).
Research Coverage:
The report analyzes the cardiovascular devices market and aims at estimating the market size and future growth potential of this market based on various segments such as products, indication and end user. The report also includes a product portfolio matrix of various cardiovascular device technologies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall cardiovascular devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights into the following pointers:
- Of Analysis of key drivers (The increase in prevalence of cardiovascular diseases, The increasing preference for minimally invasive techniques, Technological Advancements Fueling Innovation in Cardiovascular Devices, Rise in Remote Patient Monitoring), restraints (Stringent regulatory guidelines for product approval, Lack of skilled Cardiovascular Healthcare professionals), opportunities (Projected Growth in the Elderly Population, Emerging Opportunities in Biodegradable Cardiovascular Devices) and challenges (Product failures and recalls, Adverse Effects and Complications with usage of implantable cardiovascular devices).
- Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global cardiovascular devicesmarket.
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global cardiovascular devices market
- Market Development: Comprehensive information on the lucrative emerging markets by product, indication and enduser.
- Market Diversification: Exhaustive information about new product or product enhancements, growing geographies, recent developments, and investments in the global cardiovascular devices market.
- Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of product and services, and capacities of the major competitors in the global cardiovascular devices market.
Table of Contents
1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.3 MARKET SCOPE 35
1.3.1 MARKET SEGMENTATION 35
1.3.2 INCLUSIONS & EXCLUSIONS 36
1.3.3 YEARS CONSIDERED 36
1.3.4 CURRENCY CONSIDERED 37
1.4 STAKEHOLDERS 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
2.1.1 SECONDARY DATA 39
2.1.1.1 Key data from secondary sources 40
2.1.2 PRIMARY DATA 40
2.1.2.1 Key data from primary sources 42
2.1.2.2 Key industry insights 42
2.2 MARKET SIZE ESTIMATION 43
2.3 GROWTH FORECAST 45
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 48
2.5 MARKET RANKING ANALYSIS 49
2.6 STUDY ASSUMPTIONS 49
2.7 RESEARCH LIMITATIONS 49
2.7.1 METHODOLOGY-RELATED LIMITATIONS 49
2.7.2 SCOPE-RELATED LIMITATIONS 50
2.8 RISK ASSESSMENT 50
3 EXECUTIVE SUMMARY 51
4 PREMIUM INSIGHTS 55
4.1 CARDIOVASCULAR DEVICES MARKET OVERVIEW 55
4.2 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET,
BY END USER AND COUNTRY (2023) 56
4.3 CARDIOVASCULAR DEVICES MARKET: REGIONAL MIX, 2024–2029 (USD MILLION) 57
5 MARKET OVERVIEW 58
5.1 INTRODUCTION 58
5.2 MARKET DYNAMICS 58
5.2.1 DRIVERS 59
5.2.1.1 Rising incidence of cardiovascular diseases 59
5.2.1.2 Increasing accessibility to advanced high-performance devices 59
5.2.1.3 Growing preference for minimally invasive surgeries 60
5.2.1.4 Rising technological advancements in cardiovascular devices 60
5.2.1.5 Increasing trend of remote patient monitoring 60
5.2.2 RESTRAINTS 61
5.2.2.1 Stringent regulatory guidelines for product approval 61
5.2.2.2 Shortage of skilled cardiac health professionals 62
5.2.3 OPPORTUNITIES 62
5.2.3.1 Rising geriatric population and increasing uptake of CVD devices 62
5.2.3.2 Emergence of biodegradable cardiovascular devices 62
5.2.4 CHALLENGES 63
5.2.4.1 Product recalls & failures 63
5.2.4.2 Complications associated with implantable devices 63
5.3 INDUSTRY TRENDS 64
5.3.1 MINIMALLY INVASIVE PROCEDURES 65
5.3.2 WEARABLE TECHNOLOGY AND REMOTE MONITORING 65
5.3.3 PERSONALIZED MEDICINE 65
5.4 TECHNOLOGY ANALYSIS 66
5.4.1 KEY TECHNOLOGIES 66
5.4.1.1 Transcatheter aortic valve replacement (TAVR) 66
5.4.1.2 Cardiac mapping systems 66
5.4.1.3 3D-printed cardiovascular devices 67
5.4.2 COMPLEMENTARY TECHNOLOGIES 67
5.4.2.1 Robotic-assisted surgeries 67
5.4.2.2 Advanced catheter systems 67
5.4.2.3 Imaging technologies 68
5.4.3 ADJACENT TECHNOLOGIES 68
5.4.3.1 Regenerative medicine 68
5.4.3.2 Biomaterials & nanotechnology 68
5.4.3.3 Big data & cloud computing 69
5.5 PORTER’S FIVE FORCE ANALYSIS 69
5.5.1 THREAT OF NEW ENTRANTS 69
5.5.2 BARGAINING POWER OF SUPPLIERS 70
5.5.3 BARGAINING POWER OF BUYERS 70
5.5.4 THREAT OF SUBSTITUTES 70
5.5.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.6 REGULATORY LANDSCAPE 71
5.6.1 REGULATORY ANALYSIS 71
5.6.1.1 North America 71
5.6.1.1.1 US 71
5.6.1.1.2 Canada 72
5.6.1.2 Europe 72
5.6.1.3 Asia Pacific 72
5.6.1.4 Latin America 73
5.6.1.5 Middle East & Africa 73
5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
5.7 PATENT ANALYSIS 76
5.7.1 PATENT PUBLICATION TRENDS IN CARDIOVASCULAR DEVICES MARKET 76
5.7.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 77
5.8 TRADE ANALYSIS 80
5.9 PRICING ANALYSIS 80
5.10 KEY CONFERENCES & EVENTS, 2024−2025 82
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 83
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 83
5.11.2 BUYING CRITERIA 84
5.12 UNMET NEEDS/END-USER EXPECTATIONS IN CARDIOVASCULAR DEVICES MARKET 85
5.13 IMPACT OF AI/GENERATIVE AI ON CARDIOVASCULAR DEVICES MARKET 86
5.14 ECOSYSTEM ANALYSIS 86
5.15 CASE STUDY ANALYSIS 88
5.15.1 CASE STUDY 1: EVALUATION OF TAVR SYSTEM 88
5.15.2 CASE STUDY 2: SAFETY & EFFICACY ASSESSMENT OF WATCHMAN DEVICE IN ATRIAL FIBRILLATION 89
5.15.3 CASE STUDY 3: PERFORMANCE ANALYSIS OF MITRACLIP FOR THE TREATMENT OF MITRAL REGURGITATION 90
5.16 SUPPLY CHAIN ANALYSIS 90
5.17 ADJACENT MARKET ANALYSIS 92
5.17.1 CARDIAC MONITORING AND RHYTHM MANAGEMENT DEVICES MARKET 92
5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 93
5.19 CARDIOVASCULAR DEVICES MARKET: INVESTMENT & FUNDING SCENARIO 94
5.20 R&D PIPELINE ANALYSIS 95
6 CARDIOVASCULAR DEVICES MARKET, BY PRODUCT 96
6.1 INTRODUCTION 97
6.2 CARDIAC IMAGING & DIAGNOSTIC DEVICES 98
6.2.1 ECG DEVICES 100
6.2.1.1 Low costs and expanding applications to fuel market 100
6.2.2 CARDIAC ULTRASOUND IMAGING 101
6.2.2.1 Growing preference towards minimally invasive techniques to boost demand 101
6.2.3 CARDIAC COMPUTERIZED TOMOGRAPHY (CT) SCANNERS 103
6.2.3.1 Increasing preference over other diagnostic imaging methods to drive market 103
6.2.4 CARDIAC MAGNETIC RESONANCE IMAGING (MRI) 104
6.2.4.1 Increasing incidence of cardiac diseases to fuel uptake 104
6.2.5 NUCLEAR CARDIOLOGY SYSTEMS 106
6.2.5.1 Ability to assess tissue functionality and heart physiology to support market growth 106
6.2.6 CARDIAC DIAGNOSTIC CATHETERS 107
6.2.6.1 Rising focus on catheterization procedures to fuel market 107
6.3 CARDIAC RHYTHM MANAGEMENT DEVICES 109
6.3.1 PACEMAKERS 111
6.3.1.1 Growing availability of leadless and MRI-safe devices to boost demand 111
6.3.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD) 112
6.3.2.1 Increasing prevalence of arrhythmias to drive market 112
6.3.3 CARDIAC RESYNCHRONIZATION THERAPY (CRT) DEVICES 114
6.3.3.1 Ability to reduce fatigue and associated heart failure symptoms to boost demand 114
6.4 INTERVENTIONAL CARDIOLOGY DEVICES 115
6.4.1 CORONARY STENTS 118
6.4.1.1 Technological advancements in stents to fuel uptake 118
6.4.2 HEART VALVE DEVICES 120
6.4.2.1 Increasing prevalence of valve stenosis and regurgitation to fuel market 120
6.4.3 CLOSURE DEVICES 121
6.4.3.1 Utilization of self-expandable materials to drive market 121
6.4.4 SURGICAL CATHETERS 122
6.4.4.1 Rising adoption of angioplasty procedures to support market growth 122
6.4.5 GUIDEWIRES 124
6.4.5.1 Rising uptake in PCI procedures to drive market 124
6.4.6 OTHER INTERVENTIONAL CARDIOLOGY DEVICES 125
6.5 CARDIAC ASSIST DEVICES 127
6.5.1 VENTRICULAR ASSIST DEVICES 129
6.5.1.1 Rising incidence of heart failure to boost market 129
6.5.2 INTRA-AORTIC BALLOON PUMPS (IABP) 130
6.5.2.1 Product recalls to restrain market 130
6.5.3 TOTAL ARTIFICIAL HEART (TAH) 131
6.5.3.1 Growing product pipeline to fuel market 131
6.5.4 IMPELLA DEVICES 133
6.5.4.1 Increasing utility in high-risk procedures to support market growth 133
6.6 ELECTROPHYSIOLOGY DEVICES 134
6.6.1 EP CATHETERS 136
6.6.1.1 Rising incidence of chronic heart conditions to drive market 136
6.6.2 ABLATION SYSTEMS 137
6.6.2.1 Increasing utilization of radiofrequency ablation procedures to support market growth 137
6.6.3 3D MAPPING SYSTEM 139
6.6.3.1 Development of alternative technologies to hinder market 139
6.7 EXTERNAL SUPPORT DEVICES 140
6.7.1 EXTERNAL DEFIBRILLATORS 142
6.7.1.1 Adoption of user-friendly AEDs to fuel market 142
6.7.2 EXTERNAL PACEMAKERS 143
6.7.2.1 Technological advancements in leadless & implantable pacemakers to restrain market 143
6.7.3 CARDIAC COMPRESSION DEVICES 145
6.7.3.1 Reduced CPR rate to restrain market 145
6.8 MONITORING DEVICES 146
6.8.1 BLOOD PRESSURE MONITORS 148
6.8.1.1 Portability and ease of use to fuel market 148
6.8.2 PULSE OXIMETERS 149
6.8.2.1 Increasing adoption of OTC devices in home care settings to propel market 149
6.8.3 IMPLANTABLE CARDIAC MONITORS (ICM) 151
6.8.3.1 Growing focus on RPM to support market 151
7 CARDIOVASCULAR DEVICES MARKET, BY INDICATION 153
7.1 INTRODUCTION 154
7.2 CORONARY ARTERY DISEASE 155
7.2.1 ANGINA PECTORIS 156
7.2.1.1 Growing adoption of implantable monitors and ECG devices for treatment to drive market 156
7.2.2 MYOCARDIAL INFARCTION 158
7.2.2.1 Increasing demand for stents in acute cases to fuel market 158
7.3 ARRHYTHMIAS 159
7.3.1 TACHYCARDIA 161
7.3.1.1 Rising cardiac electrophysiology procedures to drive market 161
7.3.2 BRADYCARDIA 162
7.3.2.1 Rising incidence of OSA to support market growth 162
7.4 STRUCTURAL HEART DISEASE 164
7.4.1 VALVULAR HEART DISEASE 165
7.4.1.1 Rising risks of aortic stenosis to drive market 165
7.4.2 CONGENITAL HEART DISEASE 167
7.4.2.1 Potential for new therapies to fuel uptake 167
7.4.3 CARDIOMYOPATHY 168
7.4.3.1 Uptake of ICDs to drive market 168
7.4.4 CONGESTIVE HEART FAILURE 170
7.4.4.1 Growth in geriatric population to fuel market 170
7.5 INFLAMMATORY HEART DISEASE 171
7.5.1 PERICARDITIS 173
7.5.1.1 Increasing incidence due to COVID-19 to support market growth 173
7.5.2 MYOCARDITIS 175
7.5.2.1 Increasing prevalence of autoimmune diseases to support market growth 175
7.5.3 ENDOCARDITIS 176
7.5.3.1 Focus on echocardiography for clinical evaluation to drive market 176
7.6 OTHER CARDIOVASCULAR INDICATIONS 178
8 CARDIOVASCULAR DEVICES MARKET, BY END USER 180
8.1 INTRODUCTION 181
8.2 HOSPITALS & CLINCS 182
8.2.1 HIGH PURCHASING POWER OF HOSPITALS AND RISING NUMBER OF CARDIOVASCULAR PROCEDURES TO DRIVE MARKET 182
8.3 DIAGNOSTIC LABORATORIES 184
8.3.1 RISING FOCUS ON TECHNOLOGICALLY ADVANCED DIAGNOSTIC INSTRUMENTS TO SUPPORT MARKET GROWTH 184
8.4 AMBULATORY SURGERY CENTERS 185
8.4.1 INCREASING DEMAND FOR OUTPATIENT CARE AND RPM SERVICES TO PROPEL MARKET 185
8.5 OTHER END USERS 187
9 CARDIOVASCULAR DEVICES MARKET, BY REGION 189
9.1 INTRODUCTION 190
9.2 NORTH AMERICA 191
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 191
9.2.2 US 205
9.2.2.1 Increasing cases of obesity due to sedentary lifestyles to propel market 205
9.2.3 CANADA 216
9.2.3.1 Increasing funding for CVD research to support market growth 216
9.3 EUROPE 227
9.3.1 INCREASING PRODUCT APPROVALS FOR ADVANCED CARDIOVASCULAR DEVICES TO DRIVE MARKET 227
9.3.2 MACROECONOMIC OUTLOOK FOR EUROPE 227
9.4 ASIA PACIFIC 240
9.4.1 LARGE TARGET PATIENT POPULATION AND INCREASING INCIDENCE OF CVD TO PROPEL MARKET 240
9.4.2 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 240
9.5 LATIN AMERICA 252
9.5.1 BURDEN OF CONGENITAL HEART DISEASES TO DRIVE MARKET 252
9.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 253
9.6 MIDDLE EAST & AFRICA 265
9.6.1 RISING HEALTHCARE EXPENDITURE TO SUPPORT MARKET GROWTH 265
9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 265
10 COMPETITIVE LANDSCAPE 279
10.1 OVERVIEW 279
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 279
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CARDIOVASCULAR DEVICES MARKET 280
10.3 REVENUE ANALYSIS 282
10.4 MARKET SHARE ANALYSIS 283
10.4.1 RANKING OF KEY MARKET PLAYERS, 2023 285
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 285
10.5.1 STARS 285
10.5.2 EMERGING LEADERS 285
10.5.3 PERVASIVE PLAYERS 286
10.5.4 PARTICIPANTS 286
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 287
10.5.5.1 Company footprint 287
10.5.5.2 Region footprint 288
10.5.5.3 Product footprint 289
10.5.5.4 Indication footprint 290
10.5.5.5 End-user footprint 291
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 292
10.6.1 PROGRESSIVE COMPANIES 292
10.6.2 RESPONSIVE COMPANIES 292
10.6.3 DYNAMIC COMPANIES 292
10.6.4 STARTING BLOCKS 292
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 294
10.7 COMPANY VALUATION & FINANCIAL METRICS 295
10.7.1 COMPANY VALUATION 295
10.7.2 FINANCIAL METRICS 296
10.8 BRAND/PRODUCT COMPARISON 296
10.9 COMPETITIVE SCENARIO 297
10.9.1 PRODUCT LAUNCHES & APPROVALS 297
10.9.2 DEALS 298
10.9.3 EXPANSIONS 299
10.9.4 OTHER DEVELOPMENTS 299
11 COMPANY PROFILES 300
11.1 KEY PLAYERS 300
11.1.1 MEDTRONIC 300
11.1.1.1 Business overview 300
11.1.1.2 Products offered 301
11.1.1.3 Recent developments 309
11.1.1.3.1 Product launches & approvals 309
11.1.1.3.2 Deals 310
11.1.1.4 MnM view 311
11.1.1.4.1 Key strengths 311
11.1.1.4.2 Strategic choices 311
11.1.1.4.3 Weaknesses & competitive threats 311
11.1.2 ABBOTT LABORATORIES 312
11.1.2.1 Business overview 312
11.1.2.2 Products offered 313
11.1.2.3 Recent developments 321
11.1.2.3.1 Product launches & approvals 321
11.1.2.3.2 Deals 323
11.1.2.4 MnM view 323
11.1.2.4.1 Key strengths 323
11.1.2.4.2 Strategic choices 324
11.1.2.4.3 Weaknesses & competitive threats 324
11.1.3 BOSTON SCIENTIFIC CORPORATION 325
11.1.3.1 Business overview 325
11.1.3.2 Products offered 326
11.1.3.3 Recent developments 333
11.1.3.3.1 Product launches & approvals 333
11.1.3.3.2 Deals 333
11.1.3.4 MnM view 335
11.1.3.4.1 Key strengths 335
11.1.3.4.2 Strategic choices 335
11.1.3.4.3 Weaknesses & competitive threats 335
11.1.4 GE HEALTHCARE 336
11.1.4.1 Business overview 336
11.1.4.2 Products offered 337
11.1.4.3 Recent developments 339
11.1.4.3.1 Product launches & approvals 339
11.1.4.3.2 Deals 340
11.1.4.4 MnM view 341
11.1.4.4.1 Key strengths 341
11.1.4.4.2 Strategic choices 341
11.1.4.4.3 Weaknesses & competitive threats 341
11.1.5 TERUMO CORPORATION 342
11.1.5.1 Business overview 342
11.1.5.2 Products offered 343
11.1.5.3 Recent developments 347
11.1.5.3.1 Product launches & approvals 347
11.1.5.4 MnM view 348
11.1.5.4.1 Key strengths 348
11.1.5.4.2 Strategic choices 348
11.1.5.4.3 Weaknesses & competitive threats 348
11.1.6 EDWARDS LIFESCIENCES CORPORATION 349
11.1.6.1 Business overview 349
11.1.6.2 Products offered 350
11.1.6.3 Recent developments 352
11.1.6.3.1 Product launches & approvals 352
11.1.6.3.2 Deals 353
11.1.7 SIEMENS HEALTHINEERS AG 354
11.1.7.1 Business overview 354
11.1.7.2 Products offered 355
11.1.7.3 Recent developments 357
11.1.7.3.1 Product launches & approvals 357
11.1.8 JOHNSON AND JOHNSON SERVICES, INC. 358
11.1.8.1 Business overview 358
11.1.8.2 Products offered 359
11.1.8.3 Recent developments 362
11.1.8.3.1 Product launches & approvals 362
11.1.8.3.2 Deals 363
11.1.9 SAHAJANAND MEDICAL TECHNOLOGIES LIMITED 364
11.1.9.1 Business overview 364
11.1.9.2 Products offered 364
11.1.10 BAXTER INTERNATIONAL INC 366
11.1.10.1 Business overview 366
11.1.10.2 Products offered 367
11.1.10.3 Recent developments 369
11.1.10.3.1 Deals 369
11.1.11 ARTIVION, INC. 370
11.1.11.1 Business overview 370
11.1.11.2 Products offered 371
11.1.12 GETINGE AB 373
11.1.12.1 Business overview 373
11.1.12.2 Products offered 374
11.1.12.3 Recent developments 375
11.1.12.3.1 Product launches & approvals 375
11.1.12.3.2 Deals 375
11.1.13 KONINKLIJKE PHILIPS N.V. 376
11.1.13.1 Business overview 376
11.1.13.2 Products offered 377
11.1.13.3 Recent developments 379
11.1.13.3.1 Product launches & approvals 379
11.1.14 NIHON KOHDEN CORPORATION 380
11.1.14.1 Business overview 380
11.1.14.2 Products offered 381
11.1.15 BIOTRONIK SE & CO.KG. 383
11.1.15.1 Business overview 383
11.1.15.2 Products offered 383
11.1.16 LEPU MEDICAL TECHNOLOGY(BEIJING) CO., LTD. 388
11.1.16.1 Business overview 388
11.1.16.2 Products offered 388
11.1.16.3 Recent developments 394
11.1.16.3.1 Product launches & approvals 394
11.1.17 MICROPORT SCIENTIFIC CORPORATION 396
11.1.17.1 Business overview 396
11.1.17.2 Products offered 397
11.1.17.3 Recent developments 401
11.1.17.3.1 Product launches & approvals 401
11.1.18 ANGIODYNAMICS INC. 403
11.1.18.1 Business overview 403
11.1.18.2 Products offered 405
11.1.19 JAPAN LIFELINE CO., LTD. 406
11.1.19.1 Business overview 406
11.1.19.2 Products offered 407
11.1.19.3 Recent developments 410
11.1.19.3.1 Product launches & approvals 410
11.1.20 W.L. GORE & ASSOCIATES 411
11.1.20.1 Business overview 411
11.1.20.2 Products offered 411
11.1.21 B. BRAUN SE 412
11.1.21.1 Business overview 412
11.1.21.2 Products offered 414
11.2 OTHER PLAYERS 415
11.2.1 CANON MEDICAL SYSTEMS CORPORATION 415
11.2.2 PICARD MEDICAL COMPANY 416
11.2.3 BPL MEDICAL TECHNOLOGIES PVT LTD 417
11.2.4 LIFETECH SCIENTIFIC CORPORATION 418
11.2.5 ORBUSNEICH MEDICAL GROUP HOLDINGS LIMITED 419
12 APPENDIX 420
12.1 DISCUSSION GUIDE 420
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 425
12.3 CUSTOMIZATION OPTIONS 427
12.4 RELATED REPORTS 427
12.5 AUTHOR DETAILS 428
LIST OF TABLES
TABLE 1 CURRENCY CONVERSION RATES 37
TABLE 2 CARDIOVASCULAR DEVICES MARKET: STUDY ASSUMPTIONS 49
TABLE 3 CARDIOVASCULAR DEVICES MARKET: RISK ASSESSMENT ANALYSIS 50
TABLE 4 POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH DIFFERENT DEVICES 64
TABLE 5 PORTER’S FIVE FORCES ANALYSIS 69
TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 11 LIST OF PATENTS IN CARDIOVASCULAR DEVICES MARKET, 2014−2024 79
TABLE 12 IMPORT DATA FOR CARDIOVASCULAR DEVICES MARKET, BY COUNTRY,
2018–2023 (USD MILLION) 80
TABLE 13 EXPORT DATA FOR CARDIOVASCULAR DEVICES, BY COUNTRY,
2018–2023 (USD MILLION) 80
TABLE 14 CARDIOVASCULAR DEVICES MARKET: AVERAGE SELLING PRICE, BY PRODUCT (2023) 81
TABLE 15 AVERAGE SELLING PRICE TREND OF CARDIOVASCULAR DEVICES, BY REGION (2023) 81
TABLE 16 CARDIOVASCULAR DEVICES MARKET: KEY CONFERENCES & EVENTS, 2024−2025 82
TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 END USERS 83
TABLE 18 KEY BUYING CRITERIA FOR TOP 3 END USERS OF CARDIOVASCULAR DEVICES 84
TABLE 19 CARDIOVASCULAR DEVICES MARKET: UNMET NEEDS 85
TABLE 20 CARDIOVASCULAR DEVICES MARKET: END-USER EXPECTATIONS 85
TABLE 21 CARDIOVASCULAR DEVICES MARKET: IMPACT OF AI/GENERATIVE AI 86
TABLE 22 CARDIOVASCULAR DEVICES MARKET: ECOSYSTEM ANALYSIS 87
TABLE 23 CARDIOVASCULAR DEVICES MARKET: R&D PIPELINE ANALYSIS 95
TABLE 24 CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021–2023 (USD MILLION) 97
TABLE 25 CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024–2029 (USD MILLION) 97
TABLE 26 CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 98
TABLE 27 CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 98
TABLE 28 CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY REGION,
2021–2023 (USD MILLION) 99
TABLE 29 CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY REGION,
2024–2029 (USD MILLION) 99
TABLE 30 ECG DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 101
TABLE 31 ECG DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 101
TABLE 32 CARDIAC ULTRASOUND IMAGING MARKET, BY REGION,
2021–2023 (USD MILLION) 102
TABLE 33 CARDIAC ULTRASOUND IMAGING MARKET, BY REGION,
2024–2029 (USD MILLION) 103
TABLE 34 CARDIAC CT SCANNERS MARKET, BY REGION, 2021–2023 (USD MILLION) 104
TABLE 35 CARDIAC CT SCANNERS MARKET, BY REGION, 2024–2029 (USD MILLION) 104
TABLE 36 CARDIAC MRI MARKET, BY REGION, 2021–2023 (USD MILLION) 105
TABLE 37 CARDIAC MRI MARKET, BY REGION, 2024–2029 (USD MILLION) 106
TABLE 38 NUCLEAR CARDIOLOGY SYSTEMS MARKET, BY REGION,
2021–2023 (USD MILLION) 107
TABLE 39 NUCLEAR CARDIOLOGY SYSTEMS MARKET, BY REGION,
2024–2029 (USD MILLION) 107
TABLE 40 CARDIAC DIAGNOSTIC CATHETERS MARKET, BY REGION,
2021–2023 (USD MILLION) 108
TABLE 41 CARDIAC DIAGNOSTIC CATHETERS MARKET, BY REGION,
2024–2029 (USD MILLION) 108
TABLE 42 CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 109
TABLE 43 CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 109
TABLE 44 CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY REGION,
2021–2023 (USD MILLION) 110
TABLE 45 CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY REGION,
2024–2029 (USD MILLION) 110
TABLE 46 CARDIOVASCULAR DEVICES MARKET: LIST OF COMPANIES WITH KEY PRODUCTS 111
TABLE 47 PACEMAKERS MARKET, BY REGION, 2021–2023 (USD MILLION) 112
TABLE 48 PACEMAKERS MARKET, BY REGION, 2024–2029 (USD MILLION) 112
TABLE 49 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY REGION,
2021–2023 (USD MILLION) 113
TABLE 50 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY REGION,
2024–2029 (USD MILLION) 114
TABLE 51 CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET, BY REGION,
2021–2023 (USD MILLION) 115
TABLE 52 CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET, BY REGION,
2024–2029 (USD MILLION) 115
TABLE 53 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 116
TABLE 54 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 116
TABLE 55 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION,
2021–2023 (USD MILLION) 117
TABLE 56 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION,
2024–2029 (USD MILLION) 117
TABLE 57 CORONARY STENTS MARKET, BY REGION, 2021–2023 (USD MILLION) 119
TABLE 58 CORONARY STENTS MARKET, BY REGION, 2024–2029 (USD MILLION) 119
TABLE 59 HEART VALVE DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 120
TABLE 60 HEART VALVE DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 121
TABLE 61 CLOSURE DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 122
TABLE 62 CLOSURE DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 122
TABLE 63 SURGICAL CATHETERS MARKET, BY REGION, 2021–2023 (USD MILLION) 123
TABLE 64 SURGICAL CATHETERS MARKET, BY REGION, 2024–2029 (USD MILLION) 123
TABLE 65 GUIDEWIRES MARKET, BY REGION, 2021–2023 (USD MILLION) 124
TABLE 66 GUIDEWIRES MARKET, BY REGION, 2024–2029 (USD MILLION) 125
TABLE 67 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION,
2021–2023 (USD MILLION) 126
TABLE 68 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION,
2024–2029 (USD MILLION) 126
TABLE 69 CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 127
TABLE 70 CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 127
TABLE 71 CARDIAC ASSIST DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 128
TABLE 72 CARDIAC ASSIST DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 128
TABLE 73 VENTRICULAR ASSIST DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 129
TABLE 74 VENTRICULAR ASSIST DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 130
TABLE 75 INTRA-AORTIC BALLOON PUMPS MARKET, BY REGION, 2021–2023 (USD MILLION) 131
TABLE 76 INTRA-AORTIC BALLOON PUMPS MARKET, BY REGION, 2024–2029 (USD MILLION) 131
TABLE 77 TOTAL ARTIFICIAL HEART MARKET, BY REGION, 2021–2023 (USD MILLION) 132
TABLE 78 TOTAL ARTIFICIAL HEART MARKET, BY REGION, 2024–2029 (USD MILLION) 132
TABLE 79 IMPELLA DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 133
TABLE 80 IMPELLA DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 134
TABLE 81 ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 134
TABLE 82 ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 135
TABLE 83 ELECTROPHYSIOLOGY DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 135
TABLE 84 ELECTROPHYSIOLOGY DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 136
TABLE 85 EP CATHETERS MARKET, BY REGION, 2021–2023 (USD MILLION) 137
TABLE 86 EP CATHETERS MARKET, BY REGION, 2024–2029 (USD MILLION) 137
TABLE 87 ABLATION SYSTEMS MARKET, BY REGION, 2021–2023 (USD MILLION) 138
TABLE 88 ABLATION SYSTEMS MARKET, BY REGION, 2024–2029 (USD MILLION) 138
TABLE 89 3D MAPPING SYSTEMS MARKET, BY REGION, 2021–2023 (USD MILLION) 139
TABLE 90 3D MAPPING SYSTEMS MARKET, BY REGION, 2024–2029 (USD MILLION) 140
TABLE 91 EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 140
TABLE 92 EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 141
TABLE 93 EXTERNAL SUPPORT DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 141
TABLE 94 EXTERNAL SUPPORT DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 142
TABLE 95 EXTERNAL DEFIBRILLATORS MARKET, BY REGION, 2021–2023 (USD MILLION) 143
TABLE 96 EXTERNAL DEFIBRILLATORS MARKET, BY REGION, 2024–2029 (USD MILLION) 143
TABLE 97 EXTERNAL PACEMAKERS MARKET, BY REGION, 2021–2023 (USD MILLION) 144
TABLE 98 EXTERNAL PACEMAKERS MARKET, BY REGION, 2024–2029 (USD MILLION) 145
TABLE 99 CARDIAC COMPRESSION DEVICES MARKET, BY REGION,
2021–2023 (USD MILLION) 146
TABLE 100 CARDIAC COMPRESSION DEVICES MARKET, BY REGION,
2024–2029 (USD MILLION) 146
TABLE 101 CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 147
TABLE 102 CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 147
TABLE 103 CARDIOVASCULAR MONITORING DEVICES MARKET, BY REGION,
2021–2023 (USD MILLION) 147
TABLE 104 CARDIOVASCULAR MONITORING DEVICES MARKET, BY REGION,
2024–2029 (USD MILLION) 148
TABLE 105 BLOOD PRESSURE MONITORS MARKET, BY REGION, 2021–2023 (USD MILLION) 149
TABLE 106 BLOOD PRESSURE MONITORS MARKET, BY REGION, 2024–2029 (USD MILLION) 149
TABLE 107 PULSE OXIMETERS MARKET, BY REGION, 2021–2023 (USD MILLION) 150
TABLE 108 PULSE OXIMETERS MARKET, BY REGION, 2024–2029 (USD MILLION) 150
TABLE 109 IMPLANTABLE CARDIAC MONITORS MARKET, BY REGION,
2021–2023 (USD MILLION) 151
TABLE 110 IMPLANTABLE CARDIAC MONITORS MARKET, BY REGION,
2024–2029 (USD MILLION) 152
TABLE 111 CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021–2023 (USD MILLION) 154
TABLE 112 CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024–2029 (USD MILLION) 154
TABLE 113 CORONARY ARTERY DISEASE MARKET, BY TYPE, 2021–2023 (USD MILLION) 155
TABLE 114 CORONARY ARTERY DISEASE MARKET, BY TYPE, 2024–2029 (USD MILLION) 155
TABLE 115 CORONARY ARTERY DISEASE MARKET, BY REGION, 2021–2023 (USD MILLION) 156
TABLE 116 CORONARY ARTERY DISEASE MARKET, BY REGION, 2024–2029 (USD MILLION) 156
TABLE 117 CORONARY ARTERY DISEASE MARKET FOR ANGINA PECTORIS, BY REGION,
2021–2023 (USD MILLION) 157
TABLE 118 CORONARY ARTERY DISEASE MARKET FOR ANGINA PECTORIS, BY REGION,
2024–2029 (USD MILLION) 157
TABLE 119 CORONARY ARTERY DISEASE MARKET FOR MYOCARDIAL INFRACTION, BY REGION, 2021–2023 (USD MILLION) 158
TABLE 120 CORONARY ARTERY DISEASE MARKET FOR MYOCARDIAL INFRACTION, BY REGION, 2024–2029 (USD MILLION) 159
TABLE 121 ARRHYTHMIAS MARKET, BY TYPE, 2021–2023 (USD MILLION) 159
TABLE 122 ARRHYTHMIAS MARKET, BY TYPE, 2024–2029 (USD MILLION) 160
TABLE 123 ARRHYTHMIAS MARKET, BY REGION, 2021–2023 (USD MILLION) 160
TABLE 124 ARRHYTHMIAS MARKET, BY REGION, 2024–2029 (USD MILLION) 160
TABLE 125 ARRHYTHMIAS MARKET FOR TACHYCARDIA, BY REGION,
2021–2023 (USD MILLION) 161
TABLE 126 ARRHYTHMIAS MARKET FOR TACHYCARDIA, BY REGION,
2024–2029 (USD MILLION) 162
TABLE 127 ARRHYTHMIAS MARKET FOR BRADYCARDIA, BY REGION,
2021–2023 (USD MILLION) 163
TABLE 128 ARRHYTHMIAS MARKET FOR BRADYCARDIA, BY REGION,
2024–2029 (USD MILLION) 163
TABLE 129 STRUCTURAL HEART DISEASE MARKET, BY TYPE, 2021–2023 (USD MILLION) 164
TABLE 130 STRUCTURAL HEART DISEASE MARKET, BY TYPE, 2024–2029 (USD MILLION) 164
TABLE 131 STRUCTURAL HEART DISEASE MARKET, BY REGION, 2021–2023 (USD MILLION) 165
TABLE 132 STRUCTURAL HEART DISEASE MARKET, BY REGION, 2024–2029 (USD MILLION) 165
TABLE 133 VALVULAR HEART DISEASE MARKET, BY REGION, 2021–2023 (USD MILLION) 166
TABLE 134 VALVULAR HEART DISEASE MARKET, BY REGION, 2024–2029 (USD MILLION) 167
TABLE 135 CONGENITAL HEART DISEASE MARKET, BY REGION, 2021–2023 (USD MILLION) 168
TABLE 136 CONGENITAL HEART DISEASE MARKET, BY REGION, 2024–2029 (USD MILLION) 168
TABLE 137 CARDIOMYOPATHY MARKET, BY REGION, 2021–2023 (USD MILLION) 169
TABLE 138 CARDIOMYOPATHY MARKET, BY REGION, 2024–2029 (USD MILLION) 170
TABLE 139 CONGESTIVE HEART FAILURE MARKET, BY REGION, 2021–2023 (USD MILLION) 171
TABLE 140 CONGESTIVE HEART FAILURE MARKET, BY REGION, 2024–2029 (USD MILLION) 171
TABLE 141 INFLAMMATORY HEART DISEASE MARKET, BY TYPE, 2021–2023 (USD MILLION) 172
TABLE 142 INFLAMMATORY HEART DISEASE MARKET, BY TYPE, 2024–2029 (USD MILLION) 172
TABLE 143 INFLAMMATORY HEART DISEASE MARKET, BY REGION,
2021–2023 (USD MILLION) 172
TABLE 144 INFLAMMATORY HEART DISEASE MARKET, BY REGION,
2024–2029 (USD MILLION) 173
TABLE 145 INFLAMMATORY HEART DISEASE MARKET FOR PERICARDITIS, BY REGION,
2021–2023 (USD MILLION) 174
TABLE 146 INFLAMMATORY HEART DISEASE MARKET FOR PERICARDITIS, BY REGION,
2024–2029 (USD MILLION) 174
TABLE 147 INFLAMMATORY HEART DISEASE MARKET FOR MYOCARDITIS, BY REGION,
2021–2023 (USD MILLION) 175
TABLE 148 INFLAMMATORY HEART DISEASE MARKET FOR MYOCARDITIS, BY REGION,
2024–2029 (USD MILLION) 176
TABLE 149 INFLAMMATORY HEART DISEASE MARKET FOR ENDOCARDITIS, BY REGION,
2021–2023 (USD MILLION) 177
TABLE 150 INFLAMMATORY HEART DISEASE MARKET FOR ENDOCARDITIS, BY REGION,
2024–2029 (USD MILLION) 177
TABLE 151 OTHER CARDIOVASCULAR INDICATIONS MARKET, BY REGION,
2021–2023 (USD MILLION) 178
TABLE 152 OTHER CARDIOVASCULAR INDICATIONS MARKET, BY REGION,
2024–2029 (USD MILLION) 179
TABLE 153 CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021–2023 (USD MILLION) 181
TABLE 154 CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024–2029 (USD MILLION) 181
TABLE 155 CARDIOVASCULAR DEVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2023 (USD MILLION) 183
TABLE 156 CARDIOVASCULAR DEVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2029 (USD MILLION) 183
TABLE 157 CARDIOVASCULAR DEVICES MARKET FOR DIAGNOSTIC LABORATORIES,
BY REGION, 2021–2023 (USD MILLION) 184
TABLE 158 CARDIOVASCULAR DEVICES MARKET FOR DIAGNOSTIC LABORATORIES,
BY REGION, 2024–2029 (USD MILLION) 185
TABLE 159 CARDIOVASCULAR DEVICES MARKET FOR AMBULATORY SURGERY CENTERS,
BY REGION, 2021–2023 (USD MILLION) 186
TABLE 160 CARDIOVASCULAR DEVICES MARKET FOR AMBULATORY SURGERY CENTERS,
BY REGION, 2024–2029 (USD MILLION) 186
TABLE 161 CARDIOVASCULAR DEVICES MARKET FOR OTHER END USERS, BY REGION,
2021–2023 (USD MILLION) 187
TABLE 162 CARDIOVASCULAR DEVICES MARKET FOR OTHER END USERS, BY REGION,
2024–2029 (USD MILLION) 188
TABLE 163 CARDIOVASCULAR DEVICES MARKET, BY REGION, 2021–2023 (USD MILLION) 190
TABLE 164 CARDIOVASCULAR DEVICES MARKET, BY REGION, 2024–2029 (USD MILLION) 191
TABLE 165 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY COUNTRY,
2021–2023 (USD MILLION) 192
TABLE 166 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY COUNTRY,
2024–2029 (USD MILLION) 193
TABLE 167 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT,
2021–2023 (USD MILLION) 193
TABLE 168 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT,
2024–2029 (USD MILLION) 194
TABLE 169 NORTH AMERICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 194
TABLE 170 NORTH AMERICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 195
TABLE 171 NORTH AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 195
TABLE 172 NORTH AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 195
TABLE 173 NORTH AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (THOUSAND UNITS) 196
TABLE 174 NORTH AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (THOUSAND UNITS) 196
TABLE 175 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 196
TABLE 176 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 197
TABLE 177 NORTH AMERICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 197
TABLE 178 NORTH AMERICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 198
TABLE 179 NORTH AMERICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 198
TABLE 180 NORTH AMERICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 198
TABLE 181 NORTH AMERICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 199
TABLE 182 NORTH AMERICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 199
TABLE 183 NORTH AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 199
TABLE 184 NORTH AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 200
TABLE 185 NORTH AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (THOUSAND UNITS) 200
TABLE 186 NORTH AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (THOUSAND UNITS) 200
TABLE 187 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION,
2021–2023 (USD MILLION) 201
TABLE 188 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION,
2024–2029 (USD MILLION) 201
TABLE 189 NORTH AMERICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 202
TABLE 190 NORTH AMERICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 202
TABLE 191 NORTH AMERICA: ARRHYTHMIAS MARKET, BY INDICATION,
2021–2023 (USD MILLION) 202
TABLE 192 NORTH AMERICA: ARRHYTHMIAS MARKET, BY INDICATION,
2024–2029 (USD MILLION) 203
TABLE 193 NORTH AMERICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 203
TABLE 194 NORTH AMERICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 203
TABLE 195 NORTH AMERICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 204
TABLE 196 NORTH AMERICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 204
TABLE 197 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY END USER,
2021–2023 (USD MILLION) 204
TABLE 198 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY END USER,
2024–2029 (USD MILLION) 205
TABLE 199 US: KEY MACROINDICATORS 205
TABLE 200 US: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT,
2021–2023 (USD MILLION) 206
TABLE 201 US: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT,
2024–2029 (USD MILLION) 206
TABLE 202 US: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 207
TABLE 203 US: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 207
TABLE 204 US: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 208
TABLE 205 US: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 208
TABLE 206 US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 208
TABLE 207 US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 209
TABLE 208 US: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 209
TABLE 209 US: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 209
TABLE 210 US: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 210
TABLE 211 US: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 210
TABLE 212 US: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 210
TABLE 213 US: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 211
TABLE 214 US: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 211
TABLE 215 US: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 211
TABLE 216 US: CARDIOVASCULAR DEVICES MARKET, BY INDICATION,
2021–2023 (USD MILLION) 212
TABLE 217 US: CARDIOVASCULAR DEVICES MARKET, BY INDICATION,
2024–2029 (USD MILLION) 212
TABLE 218 US: CORONARY ARTERY DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 212
TABLE 219 US: CORONARY ARTERY DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 213
TABLE 220 US: ARRHYTHMIAS MARKET, BY INDICATION, 2021–2023 (USD MILLION) 213
TABLE 221 US: ARRHYTHMIAS MARKET, BY INDICATION, 2024–2029 (USD MILLION) 213
TABLE 222 US: STRUCTURAL HEART DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 214
TABLE 223 US: STRUCTURAL HEART DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 214
TABLE 224 US: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 214
TABLE 225 US: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 215
TABLE 226 US: CARDIOVASCULAR DEVICES MARKET, BY END USER,
2021–2023 (USD MILLION) 215
TABLE 227 US: CARDIOVASCULAR DEVICES MARKET, BY END USER,
2024–2029 (USD MILLION) 215
TABLE 228 CANADA: KEY MACROINDICATORS 216
TABLE 229 CANADA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT,
2021–2023 (USD MILLION) 216
TABLE 230 CANADA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT,
2024–2029 (USD MILLION) 217
TABLE 231 CANADA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 217
TABLE 232 CANADA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 218
TABLE 233 CANADA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 218
TABLE 234 CANADA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 218
TABLE 235 CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 219
TABLE 236 CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 219
TABLE 237 CANADA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 220
TABLE 238 CANADA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 220
TABLE 239 CANADA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 220
TABLE 240 CANADA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 221
TABLE 241 CANADA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 221
TABLE 242 CANADA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 221
TABLE 243 CANADA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 222
TABLE 244 CANADA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 222
TABLE 245 CANADA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION,
2021–2023 (USD MILLION) 222
TABLE 246 CANADA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION,
2024–2029 (USD MILLION) 223
TABLE 247 CANADA: CORONARY ARTERY DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 223
TABLE 248 CANADA: CORONARY ARTERY DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 223
TABLE 249 CANADA: ARRHYTHMIAS MARKET, BY INDICATION, 2021–2023 (USD MILLION) 224
TABLE 250 CANADA: ARRHYTHMIAS MARKET, BY INDICATION, 2024–2029 (USD MILLION) 224
TABLE 251 CANADA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 224
TABLE 252 CANADA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 225
TABLE 253 CANADA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 225
TABLE 254 CANADA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 225
TABLE 255 CANADA: CARDIOVASCULAR DEVICES MARKET, BY END USER,
2021–2023 (USD MILLION) 226
TABLE 256 CANADA: CARDIOVASCULAR DEVICES MARKET, BY END USER,
2024–2029 (USD MILLION) 226
TABLE 257 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT,
2021–2023 (USD MILLION) 228
TABLE 258 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT,
2024–2029 (USD MILLION) 228
TABLE 259 EUROPE: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 229
TABLE 260 EUROPE: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 229
TABLE 261 EUROPE: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 230
TABLE 262 EUROPE: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 230
TABLE 263 EUROPE: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE,
2021–2023 (THOUSAND UNITS) 230
TABLE 264 EUROPE: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE,
2024–2029 (THOUSAND UNITS) 231
TABLE 265 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 231
TABLE 266 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 232
TABLE 267 EUROPE: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 232
TABLE 268 EUROPE: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 232
TABLE 269 EUROPE: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 233
TABLE 270 EUROPE: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 233
TABLE 271 EUROPE: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 233
TABLE 272 EUROPE: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 234
TABLE 273 EUROPE: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 234
TABLE 274 EUROPE: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 234
TABLE 275 EUROPE: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE,
2021–2023 (THOUSAND UNITS) 235
TABLE 276 EUROPE: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE,
2024–2029 (THOUSAND UNITS) 235
TABLE 277 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY INDICATION,
2021–2023 (USD MILLION) 235
TABLE 278 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY INDICATION,
2024–2029 (USD MILLION) 236
TABLE 279 EUROPE: CORONARY ARTERY DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 236
TABLE 280 EUROPE: CORONARY ARTERY DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 236
TABLE 281 EUROPE: ARRHYTHMIAS MARKET, BY INDICATION, 2021–2023 (USD MILLION) 237
TABLE 282 EUROPE: ARRHYTHMIAS MARKET, BY INDICATION, 2024–2029 (USD MILLION) 237
TABLE 283 EUROPE: STRUCTURAL HEART DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 237
TABLE 284 EUROPE: STRUCTURAL HEART DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 238
TABLE 285 EUROPE: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 238
TABLE 286 EUROPE: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 238
TABLE 287 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY END USER,
2021–2023 (USD MILLION) 239
TABLE 288 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY END USER,
2024–2029 (USD MILLION) 239
TABLE 289 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT,
2021–2023 (USD MILLION) 241
TABLE 290 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT,
2024–2029 (USD MILLION) 241
TABLE 291 ASIA PACIFIC: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 242
TABLE 292 ASIA PACIFIC: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 242
TABLE 293 ASIA PACIFIC: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 243
TABLE 294 ASIA PACIFIC: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 243
TABLE 295 ASIA PACIFIC: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (THOUSAND UNITS) 243
TABLE 296 ASIA PACIFIC: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (THOUSAND UNITS) 244
TABLE 297 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 244
TABLE 298 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 245
TABLE 299 ASIA PACIFIC: CARDIAC ASSIST DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 245
TABLE 300 ASIA PACIFIC: CARDIAC ASSIST DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 245
TABLE 301 ASIA PACIFIC: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 246
TABLE 302 ASIA PACIFIC: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 246
TABLE 303 ASIA PACIFIC: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 246
TABLE 304 ASIA PACIFIC: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 247
TABLE 305 ASIA PACIFIC: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 247
TABLE 306 ASIA PACIFIC: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 247
TABLE 307 ASIA PACIFIC: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE,
2021–2023 (THOUSAND UNITS) 248
TABLE 308 ASIA PACIFIC: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE,
2024–2029 (THOUSAND UNITS) 248
TABLE 309 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY INDICATION,
2021–2023 (USD MILLION) 248
TABLE 310 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY INDICATION,
2024–2029 (USD MILLION) 249
TABLE 311 ASIA PACIFIC: CORONARY ARTERY DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 249
TABLE 312 ASIA PACIFIC: CORONARY ARTERY DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 249
TABLE 313 ASIA PACIFIC: ARRHYTHMIAS MARKET, BY INDICATION, 2021–2023 (USD MILLION) 250
TABLE 314 ASIA PACIFIC: ARRHYTHMIAS MARKET, BY INDICATION, 2024–2029 (USD MILLION) 250
TABLE 315 ASIA PACIFIC: STRUCTURAL HEART DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 250
TABLE 316 ASIA PACIFIC: STRUCTURAL HEART DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 251
TABLE 317 ASIA PACIFIC: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 251
TABLE 318 ASIA PACIFIC: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 251
TABLE 319 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY END USER,
2021–2023 (USD MILLION) 252
TABLE 320 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY END USER,
2024–2029 (USD MILLION) 252
TABLE 321 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT,
2021–2023 (USD MILLION) 253
TABLE 322 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT,
2024–2029 (USD MILLION) 254
TABLE 323 LATIN AMERICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 254
TABLE 324 LATIN AMERICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 255
TABLE 325 LATIN AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 255
TABLE 326 LATIN AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 255
TABLE 327 LATIN AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021–2023 (THOUSAND UNITS) 256
TABLE 328 LATIN AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024–2029 (THOUSAND UNITS) 256
TABLE 329 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 256
TABLE 330 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 257
TABLE 331 LATIN AMERICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 257
TABLE 332 LATIN AMERICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 258
TABLE 333 LATIN AMERICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 258
TABLE 334 LATIN AMERICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 258
TABLE 335 LATIN AMERICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 259
TABLE 336 LATIN AMERICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 259
TABLE 337 LATIN AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (USD MILLION) 259
TABLE 338 LATIN AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (USD MILLION) 260
TABLE 339 LATIN AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021–2023 (THOUSAND UNITS) 260
TABLE 340 LATIN AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024–2029 (THOUSAND UNITS) 260
TABLE 341 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION,
2021–2023 (USD MILLION) 261
TABLE 342 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION,
2024–2029 (USD MILLION) 261
TABLE 343 LATIN AMERICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 262
TABLE 344 LATIN AMERICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 262
TABLE 345 LATIN AMERICA: ARRHYTHMIAS MARKET, BY INDICATION,
2021–2023 (USD MILLION) 262
TABLE 346 LATIN AMERICA: ARRHYTHMIAS MARKET, BY INDICATION,
2024–2029 (USD MILLION) 263
TABLE 347 LATIN AMERICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 263
TABLE 348 LATIN AMERICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 263
TABLE 349 LATIN AMERICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION,
2021–2023 (USD MILLION) 264
TABLE 350 LATIN AMERICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION,
2024–2029 (USD MILLION) 264
TABLE 351 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY END USER,
2021–2023 (USD MILLION) 264
TABLE 352 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY END USER,
2024–2029 (USD MILLION) 265
TABLE 353 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021–2023 (USD MILLION) 266
TABLE 354 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024–2029 (USD MILLION) 266
TABLE 355 MIDDLE EAST & AFRICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET,
BY TYPE, 2021–2023 (USD MILLION) 267
TABLE 356 MIDDLE EAST & AFRICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET,
BY TYPE, 2024–2029 (USD MILLION) 267
TABLE 357 MIDDLE EAST & AFRICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET,
BY TYPE, 2021–2023 (USD MILLION) 268
TABLE 358 MIDDLE EAST & AFRICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET,
BY TYPE, 2024–2029 (USD MILLION) 268
TABLE 359 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY CARDIAC RHYTHM MANAGEMENT DEVICES, 2021–2023 (THOUSAND UNITS) 268
TABLE 360 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY CARDIAC RHYTHM MANAGEMENT DEVICES, 2024–2029 (THOUSAND UNITS) 269
TABLE 361 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY TYPE, 2021–2023 (USD MILLION) 269
TABLE 362 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY TYPE, 2024–2029 (USD MILLION) 270
TABLE 363 MIDDLE EAST & AFRICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 270
TABLE 364 MIDDLE EAST & AFRICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 271
TABLE 365 MIDDLE EAST & AFRICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 271
TABLE 366 MIDDLE EAST & AFRICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 271
TABLE 367 MIDDLE EAST & AFRICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE,
2021–2023 (USD MILLION) 272
TABLE 368 MIDDLE EAST & AFRICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE,
2024–2029 (USD MILLION) 272
TABLE 369 MIDDLE EAST & AFRICA: CARDIOVASCULAR MONITORING DEVICES MARKET,
BY TYPE, 2021–2023 (USD MILLION) 272
TABLE 370 MIDDLE EAST & AFRICA: CARDIOVASCULAR MONITORING DEVICES MARKET,
BY TYPE, 2024–2029 (USD MILLION) 273
TABLE 371 MIDDLE EAST & AFRICA: CARDIOVASCULAR MONITORING DEVICES MARKET,
BY TYPE, 2021–2023 (THOUSAND UNITS) 273
TABLE 372 MIDDLE EAST & AFRICA: CARDIOVASCULAR MONITORING DEVICES MARKET,
BY TYPE, 2024–2029 (THOUSAND UNITS) 273
TABLE 373 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021–2023 (USD MILLION) 274
TABLE 374 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024–2029 (USD MILLION) 274
TABLE 375 MIDDLE EAST & AFRICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 275
TABLE 376 MIDDLE EAST & AFRICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 275
TABLE 377 MIDDLE EAST & AFRICA: ARRHYTHMIAS MARKET, BY INDICATION,
2021–2023 (USD MILLION) 276
TABLE 378 MIDDLE EAST & AFRICA: ARRHYTHMIAS MARKET, BY INDICATION,
2024–2029 (USD MILLION) 276
TABLE 379 MIDDLE EAST & AFRICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2021–2023 (USD MILLION) 276
TABLE 380 MIDDLE EAST & AFRICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2024–2029 (USD MILLION) 277
TABLE 381 MIDDLE EAST & AFRICA: INFLAMMATORY HEART DISEASE MARKET,
BY INDICATION, 2021–2023 (USD MILLION) 277
TABLE 382 MIDDLE EAST & AFRICA: INFLAMMATORY HEART DISEASE MARKET,
BY INDICATION, 2024–2029 (USD MILLION) 277
TABLE 383 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021–2023 (USD MILLION) 278
TABLE 384 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024–2029 (USD MILLION) 278
TABLE 385 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES 280
TABLE 386 CARDIOVASCULAR DEVICES MARKET: DEGREE OF COMPETITION 284
TABLE 387 CARDIOVASCULAR DEVICES MARKET: REGION FOOTPRINT 288
TABLE 388 CARDIOVASCULAR MARKET: PRODUCT FOOTPRINT 289
TABLE 389 CARDIOVASCULAR DEVICES MARKET: INDICATION FOOTPRINT 290
TABLE 390 CARDIOVASCULAR DEVICES MARKET: END-USER FOOTPRINT 291
TABLE 391 CARDIOVASCULAR DEVICES MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 294
TABLE 392 CARDIOVASCULAR DEVICES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION 295
TABLE 393 CARDIOVASCULAR DEVICES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 297
TABLE 394 CARDIOVASCULAR DEVICES MARKET: DEALS, JANUARY 2021–NOVEMBER 2024 298
TABLE 395 CARDIOVASCULAR DEVICES MARKET: EXPANSIONS,
JANUARY 2021–NOVEMBER 2024 299
TABLE 396 CARDIOVASCULAR DEVICES MARKET: OTHER DEVELOPMENTS,
JANUARY 2021–NOVEMBER 2024 299
TABLE 397 MEDTRONIC: COMPANY OVERVIEW 300
TABLE 398 MEDTRONIC: PRODUCTS OFFERED 301
TABLE 399 MEDTRONIC: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–NOVEMBER 2024 309
TABLE 400 MEDTRONIC: DEALS, JANUARY 2021–NOVEMBER 2024 310
TABLE 401 ABBOTT LABORATORIES: COMPANY OVERVIEW 312
TABLE 402 ABBOTT LABORATORIES: PRODUCTS OFFERED 313
TABLE 403 ABBOTT LABORATORIES: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–NOVEMBER 2024 321
TABLE 404 ABBOTT LABORATORIES: DEALS, JANUARY 2021–NOVEMBER 2024 323
TABLE 405 BOSTON SCIENTIFIC CORPORATION.: COMPANY OVERVIEW 325
TABLE 406 BOSTON SCIENTIFIC CORPORATION.: PRODUCTS OFFERED 326
TABLE 407 BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–NOVEMBER 2024 333
TABLE 408 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2021–NOVEMBER 2024 333
TABLE 409 GE HEALTHCARE: COMPANY OVERVIEW 336
TABLE 410 GE HEALTHCARE: PRODUCTS OFFERED 337
TABLE 411 GE HEALTHCARE: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–NOVEMBER 2024 339
TABLE 412 GE HEALTHCARE: DEALS, JANUARY 2021–NOVEMBER 2024 340
TABLE 413 TERUMO CORPORATION: COMPANY OVERVIEW 342
TABLE 414 TERUMO CORPORATION: PRODUCTS OFFERED 343
TABLE 415 TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–NOVEMBER 2024 347
TABLE 416 EDWARDS LIFESCIENCES CORPORATION: COMPANY OVERVIEW 349
TABLE 417 EDWARDS LIFESCIENCES CORPORATION: PRODUCTS OFFERED 350
TABLE 418 EDWARDS LIFESCIENCES CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 352
TABLE 419 EDWARD LIFESCIENCES CORPORATION: DEALS, JANUARY 2021–NOVEMBER 2024 353
TABLE 420 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 354
TABLE 421 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 355
TABLE 422 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–NOVEMBER 2024 357
TABLE 423 JOHNSON AND JOHNSON SERVICES, INC.: COMPANY OVERVIEW 358
TABLE 424 JOHNSON AND JOHNSON SERVICES, INC.: PRODUCTS OFFERED 359
TABLE 425 JOHNSON AND JOHNSON SERVICES INC: PRODUCT LAUNCHES & APPROVALS, JANUARY 20210–NOVEMBER 2024 362
TABLE 426 JOHNSON AND JOHNSON SERVICES, INC: DEALS,
JANUARY 2021–NOVEMBER 2024 363
TABLE 427 SAHAJANAND MEDICAL TECHNOLOGIES LIMITED: COMPANY OVERVIEW 364
TABLE 428 SAHAJANAND MEDICAL TECHNOLOGIES LIMITED: PRODUCTS OFFERED 364
TABLE 429 BAXTER INTENATIONAL, INC.: COMPANY OVERVIEW 366
TABLE 430 BAXTER INTERNATIONAL, INC.: PRODUCTS OFFERED 367
TABLE 431 BAXTER INTERNATIONAL INC.: DEALS, JANUARY 2021–NOVEMBER 2024 369
TABLE 432 ARTIVION, INC.: COMPANY OVERVIEW 370
TABLE 433 ARTIVION, INC.: PRODUCTS OFFERED 371
TABLE 434 GETINGE AB: COMPANY OVERVIEW 373
TABLE 435 GETINGE AB: PRODUCTS OFFERED 374
TABLE 436 GETINGE AB: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–NOVEMBER 2024 375
TABLE 437 GETINGE AB: DEALS, JANUARY 2021–MARCH 2024 375
TABLE 438 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 376
TABLE 439 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED 377
TABLE 440 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 379
TABLE 441 NIHON KOHDEN CORPORATION: COMPANY OVERVIEW 380
TABLE 442 NIHON KOHDEN CORPORATION: PRODUCTS OFFERED 381
TABLE 443 BIOTRONIK SE & CO.KG.: COMPANY OVERVIEW 383
TABLE 444 BIOTRONIK SE & CO.KG: PRODUCTS OFFERED 383
TABLE 445 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.: COMPANY OVERVIEW 388
TABLE 446 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.: PRODUCTS OFFERED 388
TABLE 447 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.:: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 394
TABLE 448 MICROPORT SCIENTIFIC CORPORATION: COMPANY OVERVIEW 396
TABLE 449 MICROPORT SCIENTIFIC CORPORATION: PRODUCTS OFFERED 397
TABLE 450 MICROPORT SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 401
TABLE 451 ANGIODYNAMICS INC.: COMPANY OVERVIEW 403
TABLE 452 ANGIODYNAMICS INC.: PRODUCTS OFFERED 405
TABLE 453 JAPAN LIFELINE CO., LTD.: COMPANY OVERVIEW 406
TABLE 454 JAPAN LIFELINE CO., LTD.PRODUCTS OFFERED 407
TABLE 455 JAPAN LIFELINE CO., LTD: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–NOVEMBER 2024 410
TABLE 456 W.L. GORE & ASSOCIATES: COMPANY OVERVIEW 411
TABLE 457 W.L. GORE & ASSOCIATES: PRODUCTS OFFERED 411
TABLE 458 B. BRAUN SE: COMPANY OVERVIEW 412
TABLE 459 B. BRAUN SE.: PRODUCTS OFFERED 414
LIST OF FIGURES
FIGURE 1 MARKETS & REGIONS COVERED 35
FIGURE 2 RESEARCH DESIGN 38
FIGURE 3 PRIMARY SOURCES 41
FIGURE 4 PRIMARY BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 43
FIGURE 5 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS 44
FIGURE 6 TOP-DOWN APPROACH 44
FIGURE 7 IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2029) 46
FIGURE 8 CARDIOVASCULAR DEVICES MARKET: CAGR PROJECTIONS 47
FIGURE 9 DATA TRIANGULATION METHODOLOGY 48
FIGURE 10 CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 51
FIGURE 11 CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE,
2024 VS. 2029 (USD MILLION) 52
FIGURE 12 CARDIOVASCULAR DEVICES MARKET, BY INDICATION,
2024 VS. 2029 (USD MILLION) 52
FIGURE 13 CARDIOVASCULAR DEVICES MARKET, BY END USER,
2024 VS. 2029 (USD MILLION) 53
FIGURE 14 GEOGRAPHIC SNAPSHOT OF CARDIOVASCULAR DEVICES MARKET 54
FIGURE 15 INCREASING PREVALENCE OF CARDIOVASCULAR DISEASES TO PROPEL MARKET 55
FIGURE 16 HOSPITALS & CLINICS SEGMENT ACCOUNTED FOR
LARGEST MARKET SHARE IN 2023 56
FIGURE 17 ASIA PACIFIC TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 57
FIGURE 18 CARDIOVASCULAR DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 58
FIGURE 19 LEADING TRENDS 64
FIGURE 20 CARDIOVASCULAR DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 71
FIGURE 21 NUMBER OF PATENTS PUBLISHED (JANUARY 2014─SEPTEMBER 2024) 77
FIGURE 22 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR CARDIOVASCULAR DEVICES PATENTS (JANUARY 2014−SEPTEMBER 2024) 78
FIGURE 23 TOP APPLICANT COUNTRIES/REGIONS FOR CARDIOVASCULAR DEVICES
(JANUARY 2014− JULY 2024) 78
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CARDIOVASCULAR DEVICES 83
FIGURE 25 KEY BUYING CRITERIA FOR TOP 3 END USERS OF CARDIOVASCULAR DEVICES 84
FIGURE 26 CARDIOVASCULAR DEVICES MARKET: ECOSYSTEM ANALYSIS 87
FIGURE 27 CARDIOVASCULAR DEVICES MARKET: SUPPLY CHAIN ANALYSIS 91
FIGURE 28 REVENUE SHIFT FOR CARDIOVASCULAR DEVICES MARKET 93
FIGURE 29 CARDIOVASCULAR DEVICES MARKET: INVESTMENT & FUNDING SCENARIO
(2018–2022) 94
FIGURE 30 CARDIOVASCULAR DEVICES MARKET: GEOGRAPHIC SNAPSHOT 190
FIGURE 31 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET SNAPSHOT 192
FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN CARDIOVASCULAR DEVICES MARKET (2021–2023) 282
FIGURE 33 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CARDIOVASCULAR DEVICES MARKET (2023) 283
FIGURE 34 RANKING OF KEY PLAYERS IN CARDIOVASCULAR DEVICES MARKET, 2023 285
FIGURE 35 CARDIOVASCULAR DEVICES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 286
FIGURE 36 CARDIOVASCULAR DEVICES MARKET: COMPANY FOOTPRINT 287
FIGURE 37 CARDIOVASCULAR DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 293
FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 295
FIGURE 39 EV/EBITDA OF KEY VENDORS 296
FIGURE 40 CARDIOVASCULAR DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 296
FIGURE 41 MEDTRONIC: COMPANY SNAPSHOT (2024) 301
FIGURE 42 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023) 313
FIGURE 43 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023) 326
FIGURE 44 GE HEALTHCARE: COMPANY SNAPSHOT (2023) 337
FIGURE 45 TERUMO CORPORATION: COMPANY SNAPSHOT (2023) 343
FIGURE 46 EDWARDS LIFESCIENCES CORPORATION: COMPANY SNAPSHOT (2023) 350
FIGURE 47 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023) 355
FIGURE 48 JOHNSON AND JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2023) 359
FIGURE 49 BAXTER INTENATIONAL, INC.: COMPANY SNAPSHOT (2023) 367
FIGURE 50 ARTIVION, INC.: COMPANY SNAPSHOT (2023) 371
FIGURE 51 GETINGE AB: COMPANY SNAPSHOT (2023) 374
FIGURE 52 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023) 377
FIGURE 53 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2023) 381
FIGURE 54 MICROPORT SCIENTIFIC CORPORATION.: COMPANY SNAPSHOT (2023) 397
FIGURE 55 ANGIODYNAMICS INC.: COMPANY SNAPSHOT (2023) 404
FIGURE 56 JAPAN LIFELINE CO., LTD.: COMPANY SNAPSHOT (2023) 407
FIGURE 57 B. BRAUN SE: COMPANY SNAPSHOT (2023) 413
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11